Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 80Terminated 34Recruiting 29Active not recruiting 15Unknown 13Withdrawn 8Not yet recruiting 2Suspended 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 6Lymphoid 2Myeloid 1

Conditions

Myelodysplastic Syndromes 1Leukemia, Myeloid, Acute 1GATA2 Deficiency 1

Interventions

Specimen Handling 3venetoclax 2vactosertib 1regorafenib 1fludarabine phosphate 1fludarabine 1ammonium trichloro(dioxoethylene-O,O'-)tellurate 1aldesleukin 1X-Rays 1TAK-243 1Photons 1Melphalan 1KB004 1Interleukin-2 1IL32 protein, human 1Genetic Testing 1Cyclophosphamide 1CYC065 1CA-4948 1Biopsy 1Azacitidine 1Ascorbic Acid 1Actinium 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Suspended × Azacitidine × Myeloid × Clear all
NCT06454409 2025-11-19

Regorafenib in Combination With Venetoclax and Azacitidine for the Treatment of Patients With Relapsed or Refractory Acute Myeloid Leukemia

City of Hope Medical Center

Phase 1 Suspended
20 enrolled
MyeloidOther hematologic neoplasm

GATA2 Deficiency, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡